患有多发性硬化症的患者的肠道透性受损
Lenka Fialova1, Pavla Barilly2, Ivana Stetkarova2
1Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
多发性硬化症患者可能有肠道屏障功能障碍. 在接受治疗的多发性硬化患者中,克劳丁-3 (CLDN3) 水平较高,表明潜在的肠道透性,但肠道脂肪酸结合蛋白 (I-FABP) 没有显示差异.
科学领域:
- 神经免疫学 神经免疫学
- 胃肠病学 胃肠病学
- 微生物组研究 微生物组研究
背景情况:
- 肠道微生物组和肠道屏障与多发性硬化症 (MS) 病理生理学有关.
- 肠道屏障失调与MS中中枢神经系统 (CNS) 脱髓化有关.
研究的目的:
- 评估临床隔离综合征 (CIS) 和临床确定的多发性硬化症 (CDMS) 患者的肠壁完整性.
- 评估血清生物标志物丁-3 (CLDN3) 和肠脂肪酸结合蛋白 (I-FABP) 作为肠壁功能的指标.
主要方法:
- 在MS患者和对照人群中使用ELISA测量了血清CLDN3和I-FABP水平.
- 所有参与者都排除了与质相关的疾病.
- 考虑了疾病修饰药物 (DMD),免疫抑制 (IS) 或皮质类固醇对生物标志物的影响.
主要成果:
- 与对照组相比,在接受DMD或IS治疗的MS患者中,血清CLDN3水平显著升高.
- 在MS患者和对照人群之间没有观察到I-FABP血清水平的显著差异.
- 在任何研究组中,血清CLDN3和I-FABP水平都没有相关性.
结论:
- 多发性硬化症患者可能表现出肠道上皮损伤和透性增加.
- 在MS中,肠道屏障功能障碍似乎以增加的透性而不是显著的肠细胞损伤为特征.
- 血清中CLDN3水平可能作为治疗多发性硬化患者肠道功能障碍的生物标志物.
更多相关视频
05:14Assessment of Gut Barrier Integrity in Mice Using Fluorescein-Isothiocyanate-Labeled Dextran
Published on: November 18, 2022
09:24Functional Assessment of Intestinal Permeability and Neutrophil Transepithelial Migration in Mice using a Standardized Intestinal Loop Model
Published on: February 11, 2021
相关概念视频
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Factors Influencing Drug Absorption: Disease States and Pharmacology
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
